Dopamine |
- Increased density of D2 receptors |
- DA releasing agents produce psychosis |
|
- Decreased cortical DA Innervation |
- All antipsychotics are D2 receptor antagonists |
|
- Increased D4-llke receptor binding
|
- Increased striatal DA release in vivo |
|
- Alterations in D3 receptor splicing
|
|
Gultamate |
- Decreased presynaptic makers |
- NMDA receptor antagonists produce schizophrenia-like psychosis |
|
- Decreased HC AMPA and kainate receptor expression |
- Roles of NMDA receptors in development and neurotoxicity |
|
|
- Minor changes in FC NMDA receptor subunits
|
|
|
- Altered glutamate fibers in cingulate cortex |
- Partial NMDA receptor agonists have some therapeutic benefit |
|
5-HT |
- Decreased FC 5-HT2A receptor expression |
- 5-HT2 agonists (eg, LSD) are psychotominmetic |
|
- Increased FC 5-HT1A receptors |
- 5-HT2 receptors polymorphisms associated with schizophernia and clozapine response |
|
- Increased 5-HT transporter affinity |
|
|
- Developmental and trophic roles of 5-HT
|
- Atypical antipsychotics have high affinity for several 5-HT receptors |
|
GABA |
- Decreased density of FC GABAergic terminals |
- Roles of GABA in stress and neurotoxicity |
|
- Increased GABAA receptor in limbic areas |
|
|
- Altered expression of FC GABAA receptor subunits |
|
|
Decreased FC expression of glutamic acid decarboxylase |
|
|
- Altered density of cingulte GABAergic cells |
|
|
|
|